Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Darius Mitchell

Orthopaedic Surgery Texarkana, TX Medical Doctor

NPI 1992780738 CMS profile 90379

5002 Cowhorn Creek Rd, Texarkana, TX 75503

Open in the dashboard

General payments

$12,261

158 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Darius Mitchell of Texarkana, TX is reported in the CMS Open Payments database as having received $12,261 across 158 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,945 16
2024 General $1,598 25
2023 General $1,169 21
2022 General $1,788 31
2021 General $2,938 16
2020 General $1,817 25
2019 General $1,005 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darius Mitchell
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Darius Mitchell were reported at $1,945. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Darius Mitchell Orthopaedic Surgery median Middle half National median
2019 $1,005 $644 $140–$2,844 $163
2020 $1,817 $312 $75–$1,860 $114
2021 $2,938 $520 $117–$2,495 $132
2022 $1,788 $598 $128–$2,731 $149
2023 $1,169 $461 $128–$2,264 $160
2024 $1,598 $497 $134–$2,475 $164
2025 $1,945 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $6,668 92 payments
  2. Midsouth Orthopedics $4,622 12 payments
  3. Ferring Pharmaceuticals Inc. $308 16 payments
  4. Vericel Corporation $257 15 payments
  5. Bioventus LLC $176 9 payments
  6. Flexion Therapeutics, Inc. $60 3 payments
  7. Pacira Pharmaceuticals Incorporated $45 3 payments
  8. DePuy Synthes Sales Inc. $45 3 payments
  9. Stryker Corporation $26 1 payment
  10. Molnlycke Health Care US, LLC $18 1 payment
  11. Other $36 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $6,084 24 payments
  2. Education $3,437 4 payments
  3. Food and Beverage $2,740 130 payments
Products named General payments · program years 2019–2025
  1. EUFLEXXA $308 16 payments
  2. MACI $232 13 payments
  3. Arthrex Foot & Ankle and Trauma - Implants - Long Bone Trauma - Femoral Fracture $150 1 payment
  4. Arthrex Foot & Ankle and Trauma - Implants - Long Bone Trauma - Trochanteric Fracture $150 1 payment
  5. DUROLANE Orthopedicsorthopedic Surgery $109 5 payments
  6. Zilretta $60 3 payments
  7. Exparel $45 3 payments
  8. Biogel PI OrthoPro $36 2 payments
  9. MONOVISC $32 2 payments
  10. Durolane Orthopedics/Orthopedic Surgery $31 2 payments
  11. Other $196 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

166

Median for Orthopedic Surgery: 203

Drug cost

$1,189

Median for Orthopedic Surgery: $1,433

Branded share of claims

44%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 61 $429
Ondansetron Hcl Generic 46 $331
Cephalexin Generic 36 $193
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $144
Clindamycin Hcl Generic 11 $91

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$65,315

Medicare's payments for the services billed

Medicare patients

145

Average age 73

Services billed

279

88 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 28%
Depression 26%
COPD 24%
Diabetes 22%
Atrial fibrillation 21%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record